Golod E A, Kirpatovskiĭ V I, Pavlov A Iu, Ritov V B, Darenkov A F
Urol Nefrol (Mosk). 1994 Jan-Feb(1):23-5.
Whether blood plasma from 63 pyelonephritis patients can inhibit Ca-ATPase activity when compared to known toxicity marker (middle-sized molecule number) was studied. This was done to assess diagnostic potentialities of the test based on the ability of plasma from pyelonephritis patients to inhibit the test enzymatic system, i. e. Ca-ATPase activity of the microsome fraction from renal cortex in intact rats. The inhibition of Ca-ATPase activity by the plasma is shown to correlate with inflammation activity and the patients condition. In pyodestructive acute pyelonephritis this inhibition reached 60.6 +/- 3.86%, in acute serous pyelonephritis 36.02 +/- 1.54%. It follows, that the above parameter is more informative than the number of middle-sized molecules and can be introduced as one of the criteria of the patients' condition and for choice of treatment.
研究了63例肾盂肾炎患者的血浆与已知毒性标志物(中分子数量)相比是否能抑制Ca - ATP酶活性。这样做是为了根据肾盂肾炎患者血浆抑制测试酶系统(即完整大鼠肾皮质微粒体部分的Ca - ATP酶活性)的能力来评估该测试的诊断潜力。结果显示,血浆对Ca - ATP酶活性的抑制作用与炎症活动及患者病情相关。在脓性破坏性急性肾盂肾炎中,这种抑制作用达到60.6±3.86%,在急性浆液性肾盂肾炎中为36.02±1.54%。由此可见,上述参数比中分子数量更具信息价值,可作为患者病情及治疗选择的标准之一。